First Tracks Biotherapeutics (TRAX) News Today

First Tracks Biotherapeutics (NASDAQ: TRAX) shares have recently come under pressure after weak quarterly results, although continued bullish analyst ratings and a $57 price target provide some support. The stock was recently trading near $44, well above its 52-week low but below its high.

• Positive Sentiment: Wedbush forecast significant potential price appreciation for TRAX, reinforcing the bullish view that the company’s long-term opportunity may outweigh its current losses. Wedbush Forecasts Strong Price Appreciation for First Tracks Biotherapeutics
• Positive Sentiment: Barclays maintained its Buy rating on First Tracks Biotherapeutics, signaling continued confidence in the company despite near-term earnings weakness. Barclays Sticks to Its Buy Rating for First Tracks Biotherapeutics
• Positive Sentiment: HC Wainwright raised its EPS forecasts for fiscal 2027 and 2028, reducing projected losses to $3.83 and $3.84 per share, respectively. The firm retained a Buy rating and a $57 price target, implying upside from recent trading levels.
• Neutral Sentiment: Analyst coverage remains mixed: HC Wainwright’s long-term forecasts still anticipate sizable losses, but the firm expects losses to narrow substantially by 2030. The outlook suggests investors remain focused on execution and the path toward profitability.
• Negative Sentiment: HC Wainwright lowered its estimates for third-quarter and fourth-quarter 2026 EPS to losses of $0.96 and $1.00, respectively, and cut its full-year 2026 estimate to a $4.35 loss from $3.55. It also reduced its 2029 and 2030 forecasts, indicating greater expected near- and long-term cash burn.
• Negative Sentiment: The stock declined following weak earnings. First Tracks Biotherapeutics reported a quarterly loss of $0.95 per share, worse than the $0.74 consensus estimate, adding pressure to a company that analysts expect to remain unprofitable this year. First Tracks Biotherapeutics Shares Down Following Weak Earnings